Vetoquinol SA (FRA:8JM)

Germany flag Germany · Delayed Price · Currency is EUR
79.00
+1.80 (2.33%)
At close: Mar 27, 2026
Market Cap920.06M +5.8%
Revenue (ttm)532.39M -0.9%
Net Income59.96M +27.2%
EPS5.10 +27.9%
Shares Outn/a
PE Ratio15.35
Forward PE15.89
Dividend0.89 (1.16%)
Ex-Dividend DateJun 4, 2025
Volumen/a
Average Volume8
Open79.00
Previous Close77.20
Day's Range79.00 - 79.00
52-Week Range68.70 - 89.70
Betan/a
RSI48.60
Earnings DateMar 27, 2026

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA. [Read more]

Industry Pharmaceutical Preparations
Founded 1933
Employees 2,497
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 8JM

Financial Performance

In 2024, Vetoquinol's revenue was 539.20 million, an increase of 1.88% compared to the previous year's 529.27 million. Earnings were 58.69 million, an increase of 5.62%.

Financial Statements